PhotoMedex develops laser therapy for vitiligo:
This article was originally published in Clinica
PhotoMedex has submitted an 510(k) clearance application to the FDA for permission to market its XTRAC laser system for the treatment of vitiligo, a skin disease that causes a loss of pigmentation and which, the company says, affects around 2-4 million people in the US. The Radnor, Pennsylvania-based company's excimer laser system is already FDA-approved for treating psoriasis.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.